天美传媒

Philip J. Horner received a Ph.D. in physiology from Ohio State University and completed a postdoctoral fellowship at The Salk Institute for Biological Studies. Horner's research is focused on the interaction between glial and neural cells following central nervous system challenge. His area of expertise is in regenerative medicine for multiple sclerosis, neural trauma, stroke and more.

Dr. Stephanie D. Preston is the head of the ENL and a Professor of Psychology at the University of Michigan. She completed an MA and Ph.D. in Behavioral Neuroscience at the University of California, Berkeley where she studied the biological bases of hoarding in animals. This was followed by a postdoctoral fellowship in the Department of Neurology at the University of Iowa College of Medicine studying the neural substrates of decision making. She is interested in the intrinsic effects of emotion on decision making, particularly decisions about resources such as material goods, money, food, and social support.

Dr. Samuel Weiss is a professor in the Departments of Cell Biology & Anatomy and Physiology & Pharmacology at the University of Calgary Cumming School of Medicine. Dr. Weiss is the founder and was the inaugural Director of UCalgary鈥檚 Hotchkiss Brain Institute, whose mission is to translate innovative research and education into advances in neurological and mental health care.

Two major discoveries are the hallmarks of Dr. Weiss' research career. In 1985, together with Dr. Fritz Sladeczek, Dr. Weiss discovered the metabotropic glutamate receptor - now a major target for pharmaceutical research and development for neurological disease therapies. In 1992, Dr. Weiss discovered neural stem cells in the brains of adult mammals. This research has led to new approaches for brain cell replacement and repair, as well as to novel, experimental therapeutic strategies for brain cancer. As the Scientific Director of CIHR-INMHA, Dr. Weiss works with the Canadian neurosciences, mental health and addiction communities to identify research priorities, develop research funding opportunities, build partnerships and translate research evidence into policy and practice to improve the health of Canadians and people around the world. As a member of CIHR's leadership team, he participates in setting and implementing CIHR's strategic direction.

Michael Hoffer, MD, FACS鈥攁nd his 20-plus years in the Navy studying mild Traumatic Brain Injury (mTBI), tinnitus, hearing loss, and vestibular disorders on active duty service members鈥攐ffers a tremendous resource to AHRF and its Research Committee. Today, Hoffer is a Professor of Otolaryngology and Neurological Surgery at the University of Miami Health System. As a clinician-scientist, he performs both basic and clinical research along with his Otology/Neurotology practice. Hoffer focuses much of his research on traumatic damage to the inner ear and brain, including pioneering work on the treatment of noise-induced hearing loss and tinnitus, pharmaceutical countermeasures for mTBI, and optimized diagnosis and management of neurosensory disorders seen after mTBI. Hoffer received his MD from the University of California San Diego School of Medicine, did his residency at the University of Pennsylvania, held a Neurotology Fellowship at the Ear Research Foundation, and received his BS in Biology from Stanford University. He has published extensively and received research grants from the Department of Defense, National Institutes of Health, and industry.

There are more women living with stroke than ever before, a leading cause of disability in the United States. One potential cause, believes Dr. Michelle Johansen, may be the heart-brain connection. Johansen鈥檚 presentation will share how understanding the heart may allow for more accurate diagnosis and prevention of cerebrovascular disease and injury, such as that caused by stroke.

Dr. Daniela A. Bota is a UCI Health neuro-oncologist who specializes in the treatment of primary and metastatic brain and spinal cord tumors, as well as in the neurological complications of cancers.

Bota is co-director of the UCI Health Comprehensive Brain Tumor Program and is a lead investigator on several clinical trials, including novel treatments using brain tumor vaccines and the use of electrical fields to inhibit the growth of gliomas.

Bernadette Boden-Albala, MPH, DrPH, is the Founding Dean of the UC Irvine Joe C. Wen School of Population & Public Health. A renowned researcher and academic administrator with more than 30 years of experience, she holds several leadership roles within the field of public health, at the UC Irvine campus, and at the UC-system level. Boden-Albala has dedicated her career to promoting health equity for all, defining and intervening on social determinants of disease, and leading community-level health assessments and solutions. She has expertise in cardiovascular disease and stroke, emerging infectious diseases, epidemiology as well as global health.

Dr. Crino is an internationally recognized physician-scientist specializing in developmental brain disorders. His laboratory has researched mechanisms of altered brain development associated with autism, intellectual disability, and epilepsy, defining developmental disorders associated with intractable epilepsy including autism, hemimegalencephaly, focal cortical dysplasia, and tuberous sclerosis complex (TSC), which he has studied extensively. He has collaborated on identifying several new genes associated with neurodevelopmental disorders, pioneered single cell mRNA and DNA sequencing analysis in resected human tissues; and has used mouse models to plumb the effects of mTOR regulatory genes on cell development in in vitro models using immunocytochemistry, Western assay, mRNA expression analysis, gene transfection, and in vitro cell migration assays.

Before his appointment to Chairman of the UMSOM Department of Neurology, Dr. Crino was professor and vice chair for research at Temple University School of Medicine鈥檚 Shriners Hospital Pediatric Research Center in Philadelphia. Over the last 20 years, his lab has had continuous funding from the National Institutes of Health, through which he has four grants totaling $4.1 million. He has coauthored 151 peer-reviewed manuscripts, chapters, and reviews. He has been invited to lecture all over the world.

Dr. Omuro is the chief of the Division of Neuro-Oncology and Director of the Yale Brain Tumor Center. He is a graduate and former faculty of the Neuro-Oncology program at Memorial Sloan Kettering Cancer Center in New York. Dr. Omuro is an internationally renowned leader in clinical care and research in the field of brain tumors, having led pivotal research projects and clinical trials to advance the treatment of these difficult cancers. 

Education & Training:
Fellow
Memorial Sloan Kettering Cancer Center (2004)
MD
Sao Paulo School of Medicine (1995)

, is a board-certified neurosurgeon who specializes in complex cranial surgery, endovascular neurosurgery, stroke care, and neurological oncology. He is chair of the Department of Neurological Surgery at UC San Diego Health and professor of neurological surgery, radiology and neurosciences and the Don and Karen Cohn Chancellor's Endowed Chair in Neurosurgery at UC San Diego School of Medicine.
Khalessi provides both open surgical and minimally invasive, catheter-based approaches to complex neurosurgical conditions, including brain tumors, aneurysms, arteriovenous malformations (AVM), carotid disease and ischemic stroke.
Khalessi is a founding member of the Medical Device Innovation Consortium (MDIC) that advises the FDA on early clinical feasibility for emerging neurovascular devices. He serves on the NIH Interventional Advisory Panel for StrokeNet, which provides scientific oversight for federally funded research in neurovascular disease.

With a fervent passion for evidence-based medicine, I am deeply committed to medical research. My dedication is reflected in the numerous research projects I have undertaken, demonstrating my exceptional research and analytical abilities. Proficient in conventional analysis using SPSS and highly skilled in meta-analysis, I have primarily focused on observational studies, systematic reviews, and meta-analyses. Currently, I am engaged in a cohort study involving medical records, alongside several systematic reviews and meta-analyses. My work is driven by my ambition to contribute to the medical field through rigorous research and analysis.

José Biller, MD, FACP, FAAN, FANA, FAHA is the chair of the Loyola Medicine department of neurology and professor of neurology and neurological surgery at Loyola University Chicago’s Stritch School of Medicine. He attended medical school at the University of the Republic, and completed residencies in neurology at Henry Ford Hospital and Loyola University Medical Center. Dr. Biller completed a fellowship at Wake Forest University Bowman Gray School of Medicine, with a focus on Cerebrovascular Research. Dr. Biller recently received the  and was recognized for his exceptional achievements in stroke research during the American Stroke Association’s 2023 International Stroke Conference in Dallas. He also leads Loyola Medicine’s COVID-19 neurology clinic. Prior to joining Loyola, Dr. Biller led Indiana University's department of neurology for nearly 10 years. Dr. Biller served as Director of the American Board of Psychiatry and Neurology (ABPN) from 1994 to 2001, and President of the ABPN in 2001, and currently holds the title of Emeritus Director of the ABPN. 

Dr. Lakshmi Nayak serves as Director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute in Boston. She is an Associate Professor of Neurology at Harvard Medical School. She received her medical degree at Grant Medical College in Mumbai, India. She completed her residency at New York Presbyterian Hospital/ Cornell, and fellowship at Memorial Sloan-Kettering Cancer Center in New York. Her research includes development of novel therapies through preclinical and clinical studies for management of primary brain tumors including glioblastoma and primary central nervous system lymphoma, with particular focus on molecular targeted agents and immunotherapeutics, including CAR T-cell therapy.  She leads the international neurologic assessment in neuro-oncology (NANO) effort for evaluation of neurologic function in patients with brain tumors. 

Gilbert Youssef, MD is Neuro-Oncologist at Dana-Farber Cancer Institute.  He primarily treats patients with brain and spinal cord tumors, including, glioma, meningioma, ependymoma, medulloblastoma, schwannoma, lymphoma, and brain metastases.  He also treats patients who develop neurologic complications from cancer or its treatment.
He is interested in neuroimaging, while focusing on clinical endpoints in clinical trials.  He is also involved in multiple clinical trials that are ongoing at Dana-Farber.

Christopher M. Walker, PhD, is director of the Center for Vaccines and Immunity at Nationwide Children's Hospital and holds the Wilby S. Cowan Endowed Chair in Pediatric Research.





 

, is a board-certified vascular neurologist. His expertise includes caring for patients with stroke, cerebrovascular diseases, and those who require neurological critical care. Hemmen directs the Comprehensive Stroke Center at UC San Diego Health and was instrumental in establishing the center as the first certified Stroke Center of Excellence in San Diego County.
As a professor at the University of California School of Medicine Department of Neurosciences, Hemmen directs the Stroke Fellowship Program and provides leadership and education to medical students, residents and fellows.
Hemmen is the lead investigator for numerous clinical trials in cerebrovascular disease. He investigates the use of neuroprotection and reperfusion therapies after acute ischemic stroke, as well as stroke prevention, recovery and research in intracerebral hemorrhage. He also leads the cerebrovascular research and trial coordination center that conducts national and international collaborative trials and researches new cures in all areas of cerebrovascular medicine.

The brain is composed of billions of neurons forming a complex network. Improper connections of these neurons have severe consequences on the sensory, motor, and cognitive functions of the nervous system. During embryonic development, neuronal axons are guided to their target by attractive and repulsive axonal guidance molecules. We have recently demonstrated that Sonic Hedgehog (Shh) acts as a chemoattractive molecule for the axons of certain neurons in the spinal cord.
One of the objectives of Dr. Frédéric Charron's team is to identify and characterize the components of the Shh signaling pathway in axonal guidance. In addition to helping better understand the immense complexity underlying the formation of nervous system circuits, this research will aid in identifying new strategies to promote the guidance and reconnection of axons damaged by neurodegenerative diseases and brain or spinal cord injuries.